Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.

Ağaçkesen A, Karakaş H, Turan H, Bayramoğlu E, Evliyaoğlu O

Journal of clinical medicine3 Oct 2026

PMID42882122DOI10.3390/jcm15197661PepBankPUB-42882122

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In children with achondroplasia receiving vosoritide, nasal parafoveal thickness increased nominally but not significantly after false-discovery-rate correction.
In plain wordsIn children receiving vosoritide, nasal retinal thickness increased nominally, but the change was not significant after correction.
Peptide
Vosoritide
Outcome
IncreaseNasal parafoveal thickness
Study
n = 12
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Nominal p
< 0.05
before false-discovery-rate correction
Source sentences
Summary
During the 12-month follow-up, nominal increases were observed in nasal parafoveal thickness and in average, superior, and nasal RNFL thickness (p < 0.05); however, none remained significant after false-discovery-rate correction.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212201
02HumanObservational studyEfficacy outcome
In children with achondroplasia receiving vosoritide, average RNFL thickness increased nominally but not significantly after false-discovery-rate correction.
In plain wordsIn children receiving vosoritide, average retinal nerve fiber thickness increased nominally, but the change was not significant after correction.
Peptide
Vosoritide
Outcome
IncreaseAverage RNFL thickness
Study
n = 12
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Nominal p
< 0.05
before false-discovery-rate correction
Source sentences
Summary
During the 12-month follow-up, nominal increases were observed in nasal parafoveal thickness and in average, superior, and nasal RNFL thickness (p < 0.05); however, none remained significant after false-discovery-rate correction.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212202
03HumanObservational studyEfficacy outcome
In children with achondroplasia receiving vosoritide, superior RNFL thickness increased nominally but not significantly after false-discovery-rate correction.
In plain wordsIn children receiving vosoritide, superior retinal nerve fiber thickness increased nominally, but the change was not significant after correction.
Peptide
Vosoritide
Outcome
IncreaseSuperior RNFL thickness
Study
n = 12
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Nominal p
< 0.05
before false-discovery-rate correction
Source sentences
Summary
During the 12-month follow-up, nominal increases were observed in nasal parafoveal thickness and in average, superior, and nasal RNFL thickness (p < 0.05); however, none remained significant after false-discovery-rate correction.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212203
04HumanObservational studyEfficacy outcome
In children with achondroplasia receiving vosoritide, nasal RNFL thickness increased nominally but not significantly after false-discovery-rate correction.
In plain wordsIn children receiving vosoritide, nasal retinal nerve fiber thickness increased nominally, but the change was not significant after correction.
Peptide
Vosoritide
Outcome
IncreaseNasal RNFL thickness
Study
n = 12
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Nominal p
< 0.05
before false-discovery-rate correction
Source sentences
Summary
During the 12-month follow-up, nominal increases were observed in nasal parafoveal thickness and in average, superior, and nasal RNFL thickness (p < 0.05); however, none remained significant after false-discovery-rate correction.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212204
05HumanObservational studyEfficacy outcome
In children with achondroplasia receiving vosoritide, OCTA-derived vascular densities showed no significant longitudinal changes.
In plain wordsIn children receiving vosoritide, retinal vascular densities showed no significant changes over time.
Peptide
Vosoritide
Outcome
No significant changeOCTA vascular densities
Study
n = 12
Outcome group
Retinal Perfusion · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No significant longitudinal changes were detected in OCTA-derived vascular densities.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212205
06HumanObservational studySafety outcome
No clinically relevant ocular pathology was identified in children with achondroplasia during vosoritide treatment.
In plain wordsNo clinically relevant eye disease was identified in children with achondroplasia during vosoritide treatment.
Peptide
Vosoritide
Outcome
Not applicableClinically relevant ocular pathology
Study
n = 12
Outcome group
Adverse events · Eye
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
No clinically relevant ocular pathology was identified.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study, pediatric patients with genetically confirmed achondroplasia underwent standardised ophthalmologic examination, OCT, and OCTA imaging at baseline and after 12 months of vosoritide treatment.
Summary · context
A total of 12 patients and 12 controls were included.
Report a problemFND-4288212206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.